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One  of  the  unresolved  problems  concerning  the  mechanism  of  immune 
cytolysis is  the  pronounced lability of  the  enzyme,  C~4,2a, which  activates 
the third component of complement (C'3)  and which itself is derived from the 
second (C'2) and fourth (C'4) components (1). While the lability of this enzyme 
may be highly advantageous in vivo because it limits the extent of a complement 
reaction thereby preventing depletion of the  third component, it renders ex- 
ploration  of  the  enzyme  in  vitro  extremely  cumbersome.  Thus,  an  inter- 
mediate product of immune hemolysis which is characterized by the presence of 
C'4,2a on the  cell  surface, has been shown to undergo rapid decay (2)  with 
concomitant dissociation of hemolytically inactive C'2  (3).  The  cause of the 
decay to date has eluded students of complement (4, 5). 
The  present study provides a  new approach  to  the  problem.  In exploring 
the effect of sulfhydryl reagents on the hemolytic activity of human C'2, it was 
found that a greater than 10-fold enhancement of C~2 activity could be elicited 
by defined chemical modification of the C'2 molecule. Using modified C~2 for 
the generation of C'4,2a, the enzyme no longer exhibited the marked lability so 
characteristic  of  the  natural  compound.  These  observations may aid  in  al- 
leviating certain technical difficulties in research on human complement; they 
may lead to the definition of the groups responsible for activity and stability of 
the Ct4,2a enzyme; and they may eventually become of biological significance 
if applicable to enhancement of complement in vivo. 
Materials and Methods 
Preparations of the First Component of Human Complement.--C'lq, C'Ir, and C'ls were 
prepared according to the method of Lepow (6). The esterase moiety of the first component 
(7) was isolated and kindly supplied by Dr. Irwin Lepow. 
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Preparation of the Second Component of Human Complement.--Approximately  800 ml of 
fresh serum was dialyzed for 48 hr against 3  X  10 liters of a 0.008 M solution of Na 3EDTA 
of pH  5.4 and a  conductance of  1.25  millimhos per can.  The pseudoglobulin fraction thus 
obtained was separated from the euglobulin fraction by centrifugafion and dialyzed overnight 
against phosphate buffer, pH 6.0, T/2 =  0.06,  containing 0.002 M EDTA. This buffer, having 
a conductance of 4.0 millimhos per cm, will hereafter be referred to as "starting buffer." The 
dialyzed pseudoglobulin was then incubated at 37°C for 1 hr with dh'sopropyl fluorophosphate 
(DFP) at a final concentration of 10  -am to inactivate an enzyme which, like C'I esterase, has 
the ability to inactivate C'2 (and CP4) and which may, in fact, be identical with C'I esterase. 
This enzyme was shown to be present in C'2-containing fractions obtained from carboxy- 
methyl (CM) cellulose chromatography, and had previously been responsible for substantial 
inactivation of C'2 during early stages of its purification. The DFP-treated pseudoglobulln 
was then applied  to  a  7.5  )<  60 cm column containing 2000 ml of  packed  CM  cellulose, 
previously equilibrated with starting buffer. Mter the application of the sample, 10 liters of 
starting buffer was passed through the column; this process removed approximately 95% of 
the protein. C'2 was then eluted by the application of a  gradient to 0.7 ~t NaC1 in starting 
buffer. The fractions containing C'2 activity were pooled, dialyzed overnight against start- 
ing buffer, and resubjected to chromatography on CM cellulose under conditions similar to 
those used for the first chromatographic step, the only difference being that a  4.5  X  60 cm 
column was employed. This step resulted in a  4-fold purification and a  2-fold concentration 
of the material. The fractions containing C'2 activity were pooled and concentrated to ap- 
proximately 8  ml.  This sample, following further incubation with  DFP,  was  subjected  to 
preparative electrophoresis for 24 hr on a  Pevikon block at 4°C in phosphate buffer, pH 6.0, 
T/2  -~  0.05,  containing 0.0025  ~  EDTA,  and employing a  potential gradient of 3.5  v/cm. 
The fractions containing C'2 activity were pooled and concentrated to approximately 5 ml. 
The C'2 at this stage in the isolation procedure had undergone  an  approximate 1800-fold 
purification in  terms of protein,  the recovery of  C'2 hemolytic activity as  determined by 
effective molecule titration  (8)  being approximately 30%.  As a  final step  in  the isolation 
procedure, this material was subjected to chromatography on OH-apatite, a  step which will 
be described in detail elsewhere,  x Throughout the present work, the preparation of Cr2, con- 
centrated following elution from the Pevikon block, was used as the source of C'2. The protein 
concentration was 1-1.5 mg/ml. 
Preparation of the Third and Fourth Components of Human Complement.--C'3 and C'4 were 
isolated according to the method previously described (9, 10). 
Preparation of EAC'la, 4 Complex. 10 ml of a 2.5% suspension of sheep red cells sensitized 
with rabbit anti-sheep red cell antibody (EA)  were incubated at  37°C for 15 rain with 0.2 
ml of each  C'lq,  C'lr,  and C'ls,  and 0.6 ml of saline containing 5.4 X  10-  a ~  Ca  ++ and 
1.975  )<  10  -2  ~  Mg  ++.  100  #g  of  purified C'4 was  added  and incubation continued for a 
further 15 rain. The cells were washed  twice with veronal buffered saline containing 1.5  X 
10- 4 M Ca++ and 4.8 X  10  --4 ~  Mg  ++, and then resuspended in the same buffer to their orig- 
inal volume, and in this state were referred to as EAC'la,4. 
Assays for C'2 Hemolytic Activity.--One  procedure for the determination of C'2 activity 
was performed utilizing a serum reagent lacking C'2 (R~)  (11). 
To determine C'2 activity more precisely, EAC'la,4 cells were prepared as described above 
and the time of maximal formation of EAC'la,4,2 a  (tm~x) at 32°C was determined both for 
untreated C'2 and iodine-treated C'2 (see below). 0.4 ml of EAC'la,4 was incubated at 32°C 
with various amounts of C~2 mixed with an equal volume of the saline containing Ca  ++ and 
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Mg  ++ ions. The total reaction volume was adjusted to 0.8 ml with veronal-NaC1 buffer.  At 
tm~, C'EDTA (0.1 ml freshb,,mAu serum +0.1 m] 0.2 M EDTA) was added to supply the six 
subsequent complement components and incubation was allowed to proceed for 30 min. The 
tubes were then transferred to an ice bath and 2 ml ice-cold normal saline was added to stop 
the reaction. The tubes were immediately centrifuged at 0°C and the supernatants  were re- 
moved for spectrophotometric assay of the hemoglobin. 
Kinetic Analysis of the Formation and Decay of EAC'la,4,2a.--To 6 ml of a 2.5% suspension 
of EAC'la,4, prewarmed to 32°C,  was added  1 ml of a  suitable amount of purified C'2, in 
which the chelating activity of the EDTA had been overcome by the addition of an appropriate 
amount of the solution containing free Ca  ++ and Mg  ++ ions. After thorough mixing, 0.6 ml 
aliquots were removed at intervals of time and transferred to a tube containing a mixture of 
0.1 ml fresh human serum -t- 0.i ml 0.2 M EDTA previously warmed to 32°C. After incubation 
for 30 rain at 32°C, the tubes were transferred to an ice bath and processed as outlined above. 
Preparation  of tke  Fluid Phase  Complex, (C'4i,2)a  (C'3 Convertase).--This  complex was 
prepared as described previously (1) utilizing for each preparation 200 ~tg of C'4 and amounts 
of C'2 varying between 1 and  100 pg. The reaction between C'I esterase, C'4 and C'2 was 
allowed to proceed for 2 rain at 32°C and then the material was stored at 0°C. 
Treatment of (C'4i,2)a with Iodine.--Preparations  of the complex were first treated with 
DFP at a final concentration of 5 X  10  -3 M for 60 rain at 0°C to inactivate C'1 esterase. This 
measure  prevented  formation  of  additional  (C'4i,2)a  from  residual  C'2  and  C'4  subse- 
quent to iodine treatment of the reaction mixture. 
Each preparation of the complex was then divided into two equal parts, one of which was 
treated with an amount of iodine proportional to the quantity of C'2 used in its preparation; 
the complex prepared with 100/Lg of C'2 was treated with iodine at a final concentration of 
1.25 X  10  ~  M in a 50-fold molar excess of KI. This reaction was allowed to proceed at 0°C for 
15 rain, after which time no free iodine was demonstrable by potassium iodide starch paper. 
The second part was not treated with iodine and served as the control. 
C'3 Conversion, Its Detection and Quantitation.--lO0/~g  of purified C'3 was added to each 
preparation of the complex. Following a 30 rain period of incubation at 37°C, the conversion 
of C'3 to C'3i was stopped by cooling the reaction mixtures to 0°C. The degree of conversion 
was  tested  by  immunoeleetrophoresis and  quantitated  using  radioactively labeled  C'3 as 
described earlier (12). 
Treatment of C'2 with Ckemical Reagents.--One  volume of the C'2 preparation was mixed 
with an equal volume of various concentrations of each reagent tested. The concentrations of 
the reagents ranged from 10- to 1,000-fold molar excess over the C'2 concentration. The re- 
actions were allowed to proceed for 30 rain at 4°C and were then terminated  by dilution, 
dialysis,  or passage through Sephadex. 
RESULTS 
Effect of Various Sulfkydryl Reagents on the Activity of C'2.--Since some degree 
of inactivation of C'2 encountered during its isolation procedure was prevented 
by the presence of EDTA,  it was thought that the activity of C'2 might depend 
on a  reactive sulfhydryl group within the molecule. This was particularly likely 
in view of Leon's observation that C'2 is inactivated by p-hydroxymercuriben- 
zoate  (13).  In addition,  it was  found in this laboratory  that  treatment  of C'2 
with p-chloromercuribenzoate  (p-CMB)  and iodoaeetic acid reduced the hemo- 
lytic activity to 10 %, and with cyanogen bromide and N-ethylmaleimide to 60 
and  80%,  respectively.  2-Mercaptoethanol,  dithiothreitol,  cysteine,  and  glu- 1016  HEMOLYTIC ACTIVITY OF HIYMA.N COMIPLEM~ENT 
tathione  at concentrations greater than 10  -8 ~t also caused substantial reduction 
of C'2 hemolytic activity. By contrast, treatment with iodoacetamide resulted 
in marked enhancement of CI2 activity. Further analysis of this phenomenon 
showed  that  iodoacetamide  produced  no  such  enhancement  when  used  im- 
mediately  following  recrystallization.  However,  the  ability  to  enhance  the 
activity reappeared  slowly on storage.  It was,  therefore,  suspected  that  the 
enhancement was due to contaminating free iodine and not to iodoacetamide 
per se. This was, indeed, shown to be the case (Table I). 
TABLE I 
Effect of Various Sulfhydryl Reagents on the Hemolytic Aaivit  of C'2 
Hemolytic activity  Reagent  Final concentration  (% of untreated C'2) 
p-Chlommercuribenzoate 
Iodoacetic acid 
Cyanogen bromide 
N-Ethylmaleimide 
2-Mercaptoethanol 
Dithiothreitol 
Cysteine 
Glutathione 
Iodoacetamide (not recrystallized) 
Iodoacetamide (recrystallized) 
Iodine 
M 
5 X 10  -4 
5X10  ~ 
5 ×  10-~ 
5  X  10  -2 
3 X 10-~ 
5 ×  10  -8 
3 X 10--~ 
3 X 10  4 
5 X 10  4 
5 X 10  -2 
2.5 X 10-~* 
10 
10 
60 
80 
48 
38 
6 
14 
800 
100 
1200 
* Iodine diluted in 1.25 X 10  -s ~ potassium iodide. 
Effect of Iodine Treatment of C'2 Hemolytic Activi~y.--Fig.  1 shows the effect 
of various concentrations of iodine at pH 6 on the hemolytic activity of Ct2. 
As C'2 was found to be most stable at pH 6 and enhancement to be maximal 
at 2.5 X  10  -5 ~  12 at pH 6, the following method was selected for iodine treat- 
ment of C'2. One volume of the C'2 preparation (approximately 1 mg/ml) was 
mixed with an equal volume of phosphate buffer, pH 6.0, T/2  =  0.1,  contain- 
ing 5 X  10-  ~  ~r I~ and 2.5 ×  10-  3 ~t potassium iodide. The reaction mixture was 
kept for 5 rain at room temperature before it was chilled  to 0°C and suitably 
diluted for further use. The C'2 so treated will be referred to as °xyC'2. 
It was possible under these conditions to achieve a marked enhancement of 
the hemolytic activity of C'2, Fig. 2 shows the results of a  typical experiment 
to determine  the  dose response  of unmodified C'2 and °xyC'2.  y  =  per  cent 
lysis and the negative logarithm of unlysed cells [--ln(1--y)] equals the average 
number of CI2a sites per cell (8). In the experiment depicted in Fig. 2, an aver- 
age number of one site per cell was produced, when the relative concentration MARGARET  J. POLLEY  AND HANS  J. M-0LLEI~-EBES_I=~  1017 
of unmodified C'2 was 8.15 and that of °~C'2, 0.5. The factor of enhancement 
was  therefore  16.3.  A  similar degree of enhancement  was  obtained when  the 
results were  plotted  according  to  the  logarithmic  transformation  of  the  yon 
Krogh equation (Fig. 3). The dose of untreated C'2 required for 50 % hemolysis 
i  80. 
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FIG. 1. The  effect of increasing  concentrations of iodine on  the hemolytic activity of 
human C'2 contained in a partially purified preparation, and in whole human serum; and on 
guinea pig C'2 contained in whole guinea pig serum. Human serum was tested at a dilution of 
1:40 and guinea pig serum at a dilution of 1:200. 
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FIG. 2.  Dose  response  for  unmodified  C'2, and  iodine-treated C'2.  Plotted as average 
number of C'2a sites per cell [--In(I--y)]. 1018  HEMOLYTIC  ACTIVITY  OF  HUMAN  COMPLEMENT 
(y/1-y  =  1) was 16.2  times that required of °xYC~2. Formation of EACqa,4,2a 
prepared with untreated C~2 is somewhat greater than that actually measured, 
the error being due to the lability of the complex. Considering  the decay (8), 
the true extent of enhancement of C'2 activity by iodine is 13.6-fold. 
The results of a  typical experiment to determine the rate of formation and 
decay of the intermediate complex EACqa,4,2a prepared with untreated  CP2 
and chemically modified C~2 are shown in Fig. 4. In addition to the increase in 
apparent hemolytic activity of C~2 produced by iodine  treatment,  the use of 
100- 
~eated  C'2 
10. 
0.]  ........ |  o  •  ,  ,1,,.!  0.1  1  10 
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FIG. 3.  Dose response for unmodified and  iodine-treated C'2 plotted  according to  the 
logarithmic transformation of the  yon Krogh equation, y  =  per cent lysis; at 50% lysis 
y =  0.5 and y/1--y =  1 (reference 7). 
°xyCt2 had a marked effect on the half-life of EAC'la,4,2a.  Whereas the half- 
life of this complex at 32°C was 9 min when prepared with unmodified C'2, it 
increased to approximately 150 min when °xyCt2 was employed (Fig. 4). Fur- 
ther, EAC'la,4,°xy2a cells were found to be stable for several days when stored 
at 0°C. It was apparent from these results that the ~,~ was always increased to 
some extent when °xyC'2 was employed. Whereas the lm,~ utilizing unmodified 
C'2 varied only between 3 and 5 min, variations between 5 and  15 min were 
obtained with °xyC'2. Since tr.,x  varies  with  the  number  of  C'la,4  sites  per 
cell (8),  a  possible interpretation  was that the  iodine  was, in fact, modifying 
the  EAC'la,4  cells.  This was not the  case,  however,  since  iodine  under  the 
same  conditions  used for  treating  C'2  had  no  effect on  EAC'la,4,  as  meas- 
sured by t~,~. Furthermore, iodine treatment had no effect on either free solu- 
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Another possible explanation for the observed enhancement was that iodine 
might reverse inactivation which had occurred during  the process of isolation 
of Ct2. That this was not the case is demonstrated in Fig. 1. Even fresh human 
serum exhibited a  marked increase in C~2 hemolytic activity following  treat- 
ment with iodine.  Fresh guinea pig serum, however, exhibited no increase in 
C'2  hemolytic  activity  when  tested  under  similar  conditions.  Similarly,  no 
70/]  ~  2 x 10 -1 M Iodoacetamide  (Nonrecrystallized) 
....  .  ................. 
\ 
.  5 x 10-  M Iodine  "...~.~, 
~3G 
~ Untreated [C'2 Conc. x 6) 
I 
~c~ 10  zkZ~treated",,......m 
,.w  Ir~'_ t1~-  Recrys.tallized  Iodoacetamide 
2o  4o  60  //  120 
Minutes at 32°C 
FIG. 4. Rate of formation and decay at 32°C of the intermediate complex EACtla,4,2a 
utilizing unmodified C~2 and C'2 following treatment with iodine, nonrecrystaUized iodoacet- 
amide, and iodoacetamide tested immediately following recrystallizafion. Untreated C'2 was 
tested at the same concentration as that used for the chemically modified C'2 and at six times 
this concentration, tm~ for untreated C'2 was 3 rain, 5 rain for iodine-treated C'2, and 8 rain 
for iodoacetamide-treated Ct2. 
increase  in  hemolytic activity was  observed when  whole  sera from monkey, 
horse, and cow were tested following treatment with iodine. 
E~ect  of Iodine  Treatment  on  (C'4i,2)a.--An  experiment  to  determine  the 
effect of chemical modification of bound C'2 by treatment of EAC~la,4,2a with 
iodine was not technically feasible, since iodine at the concentrations required 
produced lysis of the red cells. Therefore, the fluid phase (C'4i,2)a complex was 
utiliTed for this purpose. As shown in Table II, iodine treatment of preformed 
(C~4i,2)a  caused an increase in the activity of  this  complex as  measured  by 
conversion of Ct3.90 % conversion was achieved with untreated C'3 convertase 
prepared with 100 ~g of CP2. A similar degree of conversion was observed with 
iodine-treated enzyme which was prepared with only 10 ~g of C'2. 1020  HEMOLYTIC ACTIVITY OF HUMAN COMPLEMENT 
Effect  of Sequential  Treatment  of C'2 with Sulfhydryl-Blocking  Reagents  and 
Iodine.--Table  III shows  the  effects of  treatment with  iodine,  p-CMB,  and 
recrystallized  iodoacetamide  either  singly  or  sequentially  on  the  hemolytic 
activity of C'2. Recrystallized iodoacetamide has virtually no effect, nor does 
it  prevent  enhancement  by  iodine  or  inactivation  by  p-CMB.  The  finding 
TABLE II 
Effect of Iodine  Treatment of (C'4i, 2)a on the C'3 Converting Activity of the Complex 
Amount of C'2 used in preparation 
of (C'4i,2)a 
~g 
1 
10 
20 
50 
100 
%Conver~on of C'3 
(C'4i,2)a not treated with It 
0 
40 
60 
80 
~0 
(C'4i,2)a  treated with IJ 
0 
90 
100 
100 
100 
TABLE III 
Effect of Treatment with Sulfhydryl Reagents, Either Singly or Sequentially, on the 
Hemolytic Activity of C'2 
Sulfhydryl reagent 
First treament 
Iodine 
Iodine 
p-Chloromercuribenzoate 
p-Chloromercuribenzoate 
Iodoacetamide* 
Iodoacetamide* 
Iodoacetamide* 
Second treatment 
p-Chloromercuribenzoate 
Iodine 
Iodine 
p-Chloromercuribenzoate 
Hemolytic activity 
(% of untreated  C'2) 
810 
790 
40 
780 
110 
720 
53 
--, no further treatment with stflfhydryl reagent. 
* Iodoacetamide was freshly recrystallized. 
that treatment with iodine prevented subsequent inactivation by p-CMB sug- 
gested  that both reagents  affect and compete for the  same critical  group  in 
C'2.  However,  treatment with  p-CMB  did not prevent subsequent enhance- 
ment  by  iodine.  The  latter  observation  appeared  to  contradict  the  above 
advanced hypothesis,  unless  under  the  conditions  employed,  the  iodine  was 
capable of removing the p-CMB. To find out whether it is principally possible 
to remove p-CMB from a  sulfhydryl (-SH)- containing protein by treatment 
with iodine, experiments were performed using purified C'3, since this protein MARGARET  J.  POLLEY  AND  HANS  .T.  MULLER-EBERHARD  1021 
is more readily available in larger quantities  and has been shown to contain 
two free sulfhydryl groups.  * Using identical conditions,  C~3 was treated with 
~4C-labeled p-CMB. Mter thorough dialysis, it was determined that 2 moles of 
p-CMB  were  bound per mole of protein.  Subsequent  treatment  with  iodine 
resulted in total release  of the previously bound ~4C label (Table IV). Since in 
p-CMB  the  ~4C  label  is  incorporated into  the  benzene  ring,  the  most likely 
TABLE IV 
Tke Effect of Iodine Treatment on C'3 Pre~ou~ly Treated witk l*C-p-Ckloromercuriben~oate 
Treatment  Counts* per minute per 500 tzg C'3 
14C-p-CMB  23,700 
14C-p-CMB; iodine  240 
1 mg C'3 was treated with 10  -a u uC-p-CMB for 2 hr at 0°C. Following  extensive dialysis, 
the material was divided into two equal portions, one of which was treated with 10  "~ M I2 
in 5 X 10-' M  KI for 5 rain at room temperature. Both aliquots were then subjected to further 
dialysis. 
* Counts were corrected for quenching  and efficiency  of counting by the liquid scintillation 
counter. 
TABLE V 
Iodine-Induced Enhancement of C'2 Hemolytic Activity Compared with Uptake of Iodine 
pH  Ct2 Hemolytic activity 
(% of untreated C'2) 
254 
440 
110 
Uptake of mI 
cpm~OOug* 
142,570 
118,296 
112,914 
* Preparation of partially purified C'2. 
interpretation of the  total removal of counts by the iodine treatment is  that 
under the conditions used the p-CMB was removed from the Cr3 molecules. 
The Nature of the Effect of Iodine Causing Enhancement of C~2 Activity.--The 
results presented above suggested that the iodine effect on C'2 activity was due 
to the reaction of iodine with a sulfhydryl group in  the  C'2 molecule. Further 
evidence  in  support  of  this  view  was  obtained  through  126I-uptake  studies. 
C'2 was  treated  with  usI  at  three  different pH's and  uptake  of iodine  was 
compared with enhancement of activity. Table V  shows that whereas enhance- 
ment of activity was pH dependent, being maximal at pH 6, uptakeof 126Iwas 
no greater at pH 6 than at the other two pH values. Conditions for the uptake 
experiment were such that for every 2 moles of radioactive iodine,  104 moles 
Polley, 2¢i. J., and H. J. Mtilier-Eberhard. Unpublished observations. 1022  HEMOLYTIC  ACTIVITY  OF H-U'MAN COMPLEMENT 
unlabeled iodide and  103 moles unlabeled iodine  were present.  Provided  that 
no protein in the preparation was labeled preferentially under these conditions 
and assuming a molecular weight of 115,000  for C'2 (1), it was calculated that 
at maximal enhancement of C~2 hemolytic activity, one mole of C'2 had bound 
less than 0.05 mole of iodine. It was, therefore, concluded that the iodine effect 
was not due  to uptake of iodine,  but  to oxidation of some group in  the  C'2 
molecule.  Further  proof for oxidation  as opposed to iodination  was obtained 
through  the observation that the reducing agent,  sodium  dithionite,  reversed 
the iodine effect and lowered the activity of treated C'2 to the original level or 
even below that of untreated Cr2. Moreover, subsequent treatment with iodine 
resulted in renewed enhancement of activity (Table VI). 
TABLE VI 
Effect of Sequential  Treatment with Iodine and the Reducing Agent Sodium Dithionite 
on the Hemolytic Activity of Cr2 
Chemical reagent 
Hemolytic activity 
(% of untreated C'2) 
Treatment 1  Treatment 2  Treatment 3 
Iodine  --  --  225 
Iodine  Iodine  --  6 
Iodine  Sodium dithionite  --  20 
Iodine  Sodium dithionite  Iodine  230 
--, no further treatment. 
DISCUSSION 
Treatment of CP2 with a  critical concentration of iodine has been shown to 
result in a more than 10-fold enhancement of its hemolytic activity and in the 
stabilization of the  intermediate  complex EACtla,4,2a  prepared utilizing  the 
chemically modified C'2. The precise nature  of the  induced  chemical change 
and of the groups affected has not been defined.  However, it was possible to 
eliminate certain explanations of the effect in preference to others. Thus,  the 
principal reaction involved in iodine treatment of proteins is substitution into 
the  tyrosyl residues  resulting  in  the  production  of  the  monoiodo- or  diiodo- 
tyrosyl derivative of the protein  (14).  In the present study, under conditions 
favoring maximal enhancement of the hemolytic activity of Cr2,  0.05 mole of 
iodine was bound per mole of protein. Substitution into the tyrosyl residues as 
the cause for enhancement of Cr2  activity therefore seemed very unlikely. For 
the same reason, substitution into the imidazole ring of histidine appeared an 
equally unlikely  explanation.  Further  evidence  against histidine  substitution 
being responsible for the  iodine  effect is  the  speed with  which  the  enhance- 
ment became  apparent.  Whereas  iodine  substitution  into  histidine  is  a  time 
dependent  mechanism  (14),  the  effect of iodine  on  C~2  is  apparently instan- MARGARET J. POLLEY AND HANS J. M~OLLER-EBERI~  1023 
taneons. By a process of elimination, therefore, oxidation of Ct2 was considered 
to  be  the  most probable  interpretation of  the mechanism of enhancement. 
Since sulfhydryls are the most susceptible groups in proteins to oxidation by 
iodine, it is postulated that it is this type of group that is primarily involved 
in the observed activity change, although oxidation of a functionally relevant 
carbohydrate group has not been ruled out. 
The oxidation of a  sulfhydryl group takes place by two main routes. Mild 
oxidation of simple thiols results in the formation of disulfides. When strong 
oxidizing agents are employed, the reaction can proceed via sulfenic (-SOH) 
through sulfinic (-SO,H) to the sulfonic acid stage (-SO,H). The actual mecha- 
nism  of  the  reaction  and  the  intermediates involved are  dependent  on  the 
conditions employed (13).  Two sulfhydryls can be oxidized to form a disulfide 
provided they are not sterically hindered in doing so (16). In a protein molecule 
with relatively few -SH groups present, it may be impossible for any two of 
them to form a disulfide bond. Such an example is provided by/3-1actoglobulin. 
Treatment with iodine results in conversion of its two -SH groups to sulfenyl 
iodide and even in the presence of strong oxidizing agents these groups fail to 
form a  disulfide bond. The behavior of the sulfhydryl groups in ovalbumin is 
even more complex. Of the four -SH groups present in the native protein, only 
three are reactive towards iodine. These are oxidized to sulfenyl iodides possess- 
ing varying degrees of stability, one being almost instantaneously decomposed 
to sulfenic acid, while the other two remain stable for several days (17). 
Since the poor uptake of iodine by C~2 indicates lack of substitution, forma- 
tion of a sulfenyl iodide can also be excluded. Disulfide bond formation appears 
to be precluded by the finding that the iodine effect is reversible by treatment 
with Nw2S20,, a  reducing agent which is not known to split disulfide bonds. 
However, oxidation of a disulfide bond by iodine with the resulting formation 
of two sulfonic acid derivatives (1S) cannot be excluded at present as a possible 
mechanism of enhancement. Nevertheless, the most likely interpretation is that 
the reaction of C'2 with iodine results in oxidation of one or more sulfhydryl 
groups to one of the sulfonic acid derivatives. Whether it be the sulfenic, sul- 
flnic, or sulfonic form remains to be determined. Reversal of the iodine effect 
by the reducing agent sodium dithionite lends further support to this view. 
Sequential treatment of C"2 with iodine and sulfhydryl reagents led to the 
apparently contradictory observations that whereas prior treatment with iodine 
prevented subsequent inactivation by p-CMB, prior treatment with p-CMB 
did not prevent subsequent enhancement by iodine. These findings were com- 
patible  only if  iodine under  the  conditions employed could remove p-CMB 
from the critical sulfhydryl group. That this interpretation was indeed likely 
was shown by the finding that treatment with iodine under identical conditions 
to those used with C'2 totally removed the 14C label from C'3 previously substi- 
tuted with 14C-p-CMB. 1024  HEMOLYTIC  ACTIVITY  OF  HUMAN  COMPLEMENT 
Enhancement of the activity of an enzyme by treatment with iodine is not 
unique. A 5-fold increase in the esterase activity of carboxypeptidase A follow- 
Lug treatment with iodine has been reported (18). However, in  this case  the 
iodine-induced enhancement was shown to be the result of iodine substitution 
into two reactive tyrosyl residues closely associated with the active center of 
the enzyme (19). 
In  the  present  communication,  data  are  presented  describing  the  iodine- 
induced enhancement of another enzyme: CP3 convertase. This enzyme, which 
occurs in free solution and in cell-bound form, has recently been shown to be 
composed of two subunits,  one derived from CP2 and the other from C'4 (1). 
In  contrast  to  carboxypeptidase A,  the  effect of  iodine  on  C'3  convertase 
appears to be due to oxidation of one or more critical sulfhydryl groups. The 
accumulated evidence indicates  that  the increase in  activity and stability of 
the enzyme results solely from the modification of its C'2 subunit. The critical 
modification can be affected by treating native  C'2  before it enters into the 
complex with CI4 or by treating the  C'4,2a complex. Since both activity and 
stability  of  the  enzyme are  affected, one might  postulate  that  two  distinct 
groups in the CP2 portion are involved, one located in the active site, the other 
in the combining region. Alternatively, one could visualize the iodine effect to 
be caused by the modification of only one critical group which  allosterically 
controls the  active as  well  as  the  combining site.  Further elucidation of the 
iodine effect will  have  to await the  preparation of larger amounts  of highly 
purified C'2  for chemical analyses,  a  task  which  is  rendered difficult by the 
exceedingly low concentration of C'2 in serum. 
SUMMARY 
A  method has been described for the  chemical modification of human  C'2 
which  results  in  a  pronounced enhancement of its  hemolytic activity and  a 
marked  increase  in  the  stability  of  the  intermediate  complex  EACqa,4,2a 
prepared with the modified C'2. Both effects are fully explained by the observed 
increase in activity and stability of the C'3 converting enzyme, C'4,2a, following 
its generation with modified C~2. Evidence has been presented in support of 
the hypothesis that  the modification resulting from treatment of CI2  with a 
critical concentration of iodine consists of oxidation of one or more sulfhydryl 
group within the molecule. 
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